Patent ID: 7160918

Claim:
A method of inhibiting plasminogen activator inhibitor-1 in a mammal comprising administering to a mammal in need thereof a pharmaceutically effective amount of compound of formula: wherein: R 1 is C 1 –C 8 alkyl, C 3 –C 6 cycloalkyl, —CH 2 —C 3 –C 6 cycloalkyl, pyridinyl, —CH 2 -pyridinyl, phenyl or benzyl, the rings of the cycloalkyl, pyridinyl, phenyl and benzyl groups are optionally substituted by from 1 to 3 groups selected from the group consisting of halogen, C 1 –C 6 alkyl, C 1 –C 3 perfluoroalkyl, —O—C 1 –C 3 perfluoroalkyl, C 1 –C 3 alkoxy, —OH, —NH 2 , and —NO 2 ; R 2 is hydrogen, C 1 –C 6 alkyl, C 3 –C 6 cycloalkyl, —CH 2 —C 3 –C 6 cycloalkyl, or C 1 –C 3 perfluoroalkyl; R 3 is hydrogen, halogen, C 1 –C 6 alkyl, C 1 –C 3 perfluoroalkyl, C 1 –C 6 alkoxy, C 3 –C 6 cycloalkyl, —CH 2 —C 3 –C 6 cycloalkyl, —NH 2 , or —NO 2 ; R 4 is phenyl, benzyl, benzyloxy, pyridinyl, or —CH 2 -pyridinyl, wherein the rings of these groups are optionally substituted by 1 to 3 groups selected from the group consisting of halogen, C 1 –C 3 alkyl, C 1 –C 3 perfluoroalkyl, —O—C 1 –C 3 perfluoroalkyl, C 1 –C 3 alkoxy, —OH, —NH 2 , and —NO 2 ; R 8 is hydrogen, C 1 –C 6 alkyl, C 3 –C 6 cycloalkyl, —CH 2 —C 3 –C 6 cycloalkyl, C 1 –C 3 perfluoroalkyl, aryl, substituted aryl, alkyl-aryl, or substituted alkyl-aryl; and R 9 is hydrogen, C 1 –C 6 alkyl, C 3 –C 6 branched alkyl, C 1 –C 6 hydroxyalkyl, 4-hydroxybenzyl, 3-indolylymethylene, 4-imidazolylmethylene, HSCH 2 —, CH 3 SCH 2 CH 2 —, H 2 NC(═O)CH 2 —, H 2 NC(═O)CH 2 CH 2 —, HO 2 CCH 2 —, HO 2 CCH 2 CH 2 —, H 2 NCH 2 CH 2 CH 2 CH 2 —, H 2 NC(═NH)NHCH 2 CH 2 CH 2 —, or taken together with R 8 , —CH 2 CH 2 CH 2 —; or a pharmaceutically acceptable salt or ester form thereof.